May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Is Peripheral Retinal Dysfunction a Reason for Stopping Vigabatrin?
Author Affiliations & Notes
  • P.A. Gonzalez
    Ophthalmology, University of Glasgow, Glasgow, United Kingdom
  • D. Keating
    Ophthalmology, University of Glasgow, Glasgow, United Kingdom
  • M.J. Brodie
    Medicine, Epilepsy Unit, Glasgow, United Kingdom
  • S. Parks
    Ophthalmology, University of Glasgow, Glasgow, United Kingdom
  • Footnotes
    Commercial Relationships  P.A. Gonzalez, None; D. Keating, None; M.J. Brodie, None; S. Parks, None.
  • Footnotes
    Support  Chief Scientist Office Grant
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4552. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.A. Gonzalez, D. Keating, M.J. Brodie, S. Parks; Is Peripheral Retinal Dysfunction a Reason for Stopping Vigabatrin? . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4552.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To decide if peripheral retinal neuro–retinal toxicity in people on vigabatrin (VGB) outweighs the benefits of being seizure free. Methods:A long term longitudinal study is ongoing to objectively assess the progression of neuro–retinal toxicity associated with longterm VGB therapy in 180 patients, 40 of whom have had repeat assessments. All patients had Wide Field multifocal electroretinograms (wf mfERG), logMar visual acuity, colour vision assessment, static perimetry and ERG. In addition visual quality of life and epilepsy–related quality of life were assessed using questionnaires VFQ–35 and QUOLIE –31 repectively. Results:The difference in P1 latency between central and peripheral responses on wf MFERG is the best correlation with visual field defects. However, the questionnaires show people on VGB are quite concerned to stop the drug and unconcerned of the visual defects. Conclusion: Patient opinion should be considered in the decision to discontinue VGB in people with epilepsy.

Keywords: drug toxicity/drug effects • electrophysiology: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×